CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Axial Lumbosacral Interbody Fusion Coverage Criteria

Defines coverage and medical necessity stance for axial (presacral/transsacral) lumbosacral interbody fusion for Commercial Products of Blue Cross Blue Shield - Rhode Island; applies to providers treating degenerative spine disease at L4-S1.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAxial Lumbosacral Interbody Fusion Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 2, 2023

Next Review DateN/A

Key ActionDo not authorize axial lumbosacral interbody fusion for Commercial Products because it is considered not medically necessary due to insufficient evidence.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessarycoverage stance for Commercial Products

22586listed in coding section

Insufficient evidencerationale for NMN

Commercial onlyapplicability

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not Medically Necessary

Coverage determination

Commercial Products coverage stance: Axial lumbosacral interbody fusion is considered not medically necessary for Commercial Products because the evidence is insufficient to determine the effects of the technology on health outcomes.

Systematic review and comparative studies are limited by lack of prospective comparative data; fusion rates may be lower versus transforaminal approaches and complication rates may be increased for 2-level procedures.

The U.S. Food and Drug Administration has cleared multiple anterior spinal intervertebral body fixation device systems through the 510(k) pathway. These devices are not intended to treat severe scoliosis, severe spondylolisthesis (grades 3 and 4), tumor, or trauma. They are also not indicated for vertebral compression fractures or any condition that compromises the mechanical integrity of the vertebral body. Use of these systems is limited to anterior supplemental fixation at the L5–S1 or L4–S1 disc spaces in conjunction with a legally marketed facet or pedicle screw system.

For Blue Cross Blue Shield of Rhode Island Commercial Products, axial lumbosacral interbody fusion is considered not medically necessary. The policy determination is based on an assessment that the available evidence is insufficient to determine the effects of this technology on health outcomes.

Provider Requirements and Actions

Prior Authorization

Prior authorization is not required for this procedure.

Note

Benefit Verification Recommended

Verify member benefits and coverage prior to scheduling. Benefits may vary between groups and contracts; consult the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for coverage determinations and whether the service is considered not medically necessary or not covered.

Documentation Required

Clinical Background

Axial lumbosacral interbody fusion (also called presacral or transsacral fusion) is a minimally invasive anterior approach providing access to the L4–S1 disc spaces, commonly performed at L5–S1, under fluoroscopic guidance. The technique uses a small incision lateral to the coccyx and a blunt pin introducer advanced along the anterior sacral surface, with graduated dilators creating a working channel for disc preparation, nucleus debulking, and implant insertion.

Potential advantages of the approach include preservation of the annulus and paraspinous soft tissues. Limitations include reduced visualization of intracanal pathology and increased fluoroscopic exposure. Reported risks specific to this technique include bowel perforation and vascular or nerve injury.

Operative steps typically document fluoroscopic guidance, the presacral/transsacral approach, disc space preparation and grafting, implant placement (including distraction of the disc space), and any supplemental posterior fixation such as percutaneous pedicle or facet screws when used.

Key Definitions

Axial lumbosacral interbody fusion

TermAxial lumbosacral interbody fusion (presacral/transsacral)

DefinitionMinimally invasive anterior approach providing access to L4-S1 disc spaces for interbody fusion performed under fluoroscopic guidance.

Key advantagesPreserves the annulus and paraspinous soft tissue structures.

Limitations/risksIncreased fluoroscopy exposure; inability to address intracanal pathology or directly visualize discectomy; risks include bowel perforation and vascular or nerve injury.

ApplicabilityPolicy applies to Commercial Products only; see related policies for Medicare Advantage.

Interbody fusion

TermInterbody fusion

DefinitionSurgical procedure that fuses two adjacent vertebral bodies of the spine.

IndicationsMay be performed for spinal stenosis with instability, spondylolisthesis, scoliosis, post-discectomy, or adjacent-level disc disease.

Anatomic focusLumbar spine (commonly L4-S1 in the context of axial approaches).